Bioceres Crop Solutions (BIOX) - 2022 Q4 - Earnings Call Presentation

Financial Performance - Bioceres Crop Solutions achieved record comparable revenues for both Q4 2022 and FY22, with increases of 44% and 62% year-over-year, respectively[10] - Baseline Adjusted EBITDA reached $17.7 million for Q4 2022 and $61.9 million for the full year[10] - Total revenue reached $334.8 million for the fiscal year ended June 30, 2022, compared to $209.5 million in the previous fiscal year[39] - Gross profit was $126.5 million, with a gross profit percentage of 38%[39] HB4 Wheat - HB4 Wheat revenues amounted to $12.4 million, representing a 94% increase compared to the prior year's contributed goods number[11] - Gross margin for HB4 Wheat increased from 42% to 53%[14] Regulatory Approvals & Integration - Key regulatory clearances were obtained for HB4 Wheat and Soy from various countries, including the U.S., Australia, New Zealand, Nigeria, and China[11] - The merger with Marrone Bio Innovations, Inc, now ProFarm Group, was successfully completed[11] - The company is on track to deliver cost synergies of $8 million from the ProFarm integration[20] Balance Sheet - Total assets reached $518.3 million as of June 30, 2022[40] - Total liabilities amounted to $359.5 million[43] - The company executed financing agreements, including new secured convertible notes due in 2026, bringing in $55 million in proceeds[38]